Welcome to our dedicated page for RXO news (Ticker: $RXO), a resource for investors and traders seeking the latest updates and insights on RXO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RXO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RXO's position in the market.
RXO announced its first-quarter results for 2024, with an 11% year-over-year increase in brokerage volume. The company saw growth in full-truckload and less-than-truckload volume, with a companywide gross margin of 17.4%. Despite a net loss of $15 million, RXO remains focused on gaining market share and delivering earnings growth. The company expects continued growth in brokerage volumes and projects an adjusted EBITDA increase for the second quarter.
RXO (NYSE: RXO) will have its chief financial officer and senior market strategist participating in the Oppenheimer 19th Annual Industrial Growth Conference on May 6, 9-9:35 a.m. EDT. A webcast and replay will be available at http://investors.rxo.com.
